There are a number of ongoing trials that are actively recruiting participants and that are relevant to this appraisal. Some of these trials are investigating the optimum sequences of treatment. Full details of ongoing research can be found at the National Institute for Health Research Clinical Research Network, ClinicalTrials.gov and ISRCTN registry.
The Assessment Group considered that the following well-conducted RCTs reporting health-related utility values in accordance with the NICE methods guide could be of value:
RCTs to investigate the effectiveness of sunitinib compared with best supportive care in people who are unsuitable or have contraindications for immunotherapy and who have a poor or intermediate prognosis.
The Committee considered that rigorous data collection is needed on the life-extending benefits of sunitinib when no second-line treatments are given.